Editorial

Diagnostics, Risk Factors, Treatment and Outcomes of Acute Kidney Injury in a New Paradigm

Charat Thongprayoon 1,†, Panupong Hansrivijit 2,†, Karthik Kovvuru 3, Swetha R. Kanduri 3, Aldo Torres-Ortiz 4, Prakrati Acharya 5, Maria L. Gonzalez-Suarez 3, Wisit Kaewput 6, Tarun Bathini 7 and Wisit Cheungpasitporn 3,*

1 Division of Nephrology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA; charat.thongprayoon@gmail.com
2 Department of Internal Medicine, University of Pittsburgh Medical Center Pinnacle, Harrisburg, PA 17105, USA; hansrivijitp@upmc.edu
3 Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA; kkovvuru@umc.edu (K.K.); skanduri@umc.edu (S.R.K.); mgonzalesuarez@umc.edu (M.L.G.); wcueungpasitporn@gmail.com (W.C.)
4 Department of Medicine, Ochsner Medical Center, New Orleans, LA 70121, USA; Aldo_t86@hotmail.com
5 Division of Nephrology, Department of Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA; prakrati.c.acharya@gmail.com
6 Department of Military and Community Medicine, Pramongkutklao College of Medicine, Bangkok 10400, Thailand; wisitnephro@gmail.com
7 Department of Internal Medicine, University of Arizona, Tucson, AZ 85724, USA; tarunjacob@gmail.com

* Correspondence: wcheungpasitporn@gmail.com; Tel.: +1-601-984-5670; Fax: +1-601-984-5765
† Co-first authors.

Received: 9 April 2020; Accepted: 10 April 2020; Published: 13 April 2020

Abstract: Acute kidney injury (AKI) is a common clinical condition among patients admitted in the hospitals. The condition is associated with both increased short-term and long-term mortality. With the development of a standardized definition for AKI and the acknowledgment of the impact of AKI on patient outcomes, there has been increased recognition of AKI. Two advances from past decades, the usage of computer decision support and the discovery of AKI biomarkers, have the ability to advance the diagnostic method to and further management of AKI. The increasingly widespread use of electronic health records across hospitals has substantially increased the amount of data available to investigators and has shown promise in advancing AKI research. In addition, progress in the finding and validation of different forms of biomarkers of AKI within diversified clinical environments and has provided information and insight on testing, etiology and further prognosis of AKI, leading to future of precision and personalized approach to AKI management. In this this article, we discussed the changing paradigms in AKI: from mechanisms to diagnostics, risk factors, and management of AKI.

Keywords: acute kidney injury; acute renal failure; biomarkers; critical care; renal replacement therapy; risk factors outcomes; predictors

1. Introduction

Acute kidney injury (AKI) is a highly complicated clinical disorder that is widely characterized by rapid rate of reduced rate of glomerular filtration (GFR), demonstrated by a rise in serum creatinine (SCr) concentration or oliguria, or both [1–5]. AKI is common among hospitalized patients, affecting approximately 10%–20% of hospitalized patients, of whom 10% require renal
replacement therapy (RRT) [6–11]. Among critically ill patients, the incidence of AKI has been reported as high as 45–50% [2,12]. AKI is associated with significant morbidity, mortality, extra cost incurred in the hospitalization process, longer stay in the hospital, and long-term consequences, including chronic kidney disease (CKD) and end-stage kidney disease (ESKD) [13–16]. In the United States, AKI is associated with high hospitalization costs that range from $5.4 to $24.0 billion [17]. Overall mortality rate at 30 days post AKI is as high as 24% [18]. Each year, around 1.7 million people are globally thought to die from AKI [19].

In the recent years, there has been significant progress in the discovery and validation of AKI biomarkers in a number of clinical settings and has provided information and insight on diagnosis, prognosis as well as etiology of AKI [20]. Furthermore, the increasingly widespread use of electronic health records (EHR) across hospitals has substantially increased the amount of data available to investigators and has shown promise in advancing AKI research [21,22]. In this this article, we discussed the changing paradigms in AKI: from mechanisms to diagnostics, risk factors, and management of AKI.

2. Definition of AKI, Persistent AKI, and Renal Recovery after AKI

2.1. Definition of AKI

In 2012, the Kidney Disease Improving Global Outcomes (KDIGO) [23] gave out guidelines on the management of AKI to make the diagnosis process of the condition standardized and the severity of the disease based on absolute or relative increases in SCr and further progressive extent of oliguria, which built off of the RIFLE criteria [24] and the AKIN criteria [25]. Table 1. KDIGO describe AKI as a condition that comprise of one or more of the following: (1) an increase in SCr level ≥0.3 mg/dL (≥26.5 μmol/L) within 48 h, or (2) an increase in SCr level to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days, or (3) a urine volume of less than <0.5 mL/kg/h for 6 h or longer.

| Stage | Serum Creatinine | Urine output |
|-------|------------------|--------------|
| 1     | 1.5–1.9 times baseline OR 0.3 mg/dL increase | <0.5 mL/kg/h for 6–12 h |
| 2     | 2.0–2.9 times baseline | <0.5 mL/kg/h for ≥12 h |
| 3     | 3.0 times baseline OR Increase in serum creatinine to ≥4.0 mg/dL OR initiation of replacement therapy | <0.3 mL/kg/h for ≥24 h OR anuria for ≥12 h |

2.2. Baseline SCr, Adjust SCr for Fluid Balance, and Body Weights for Urine Output Criterion

Establishing the baseline SCr is very much important in AKI diagnosis and classification [26,27]. Inaccurate determination of the baselines SCr can lead into misclassification of AKI and additionally impact the overall prognostication of the outcomes associated to AKI [28]. SCr at the outpatient is actually a very vigorous assessment of the renal function. The process is so robust such that it is more effective at the outpatient compared to the inpatients. This is mainly because it usually represents a kind of steady state and is not altered by the index critical condition of the illness [29]. When several preadmission SCr measurements are available, the use of minimum value of the preadmission SCr as the baseline SCr can detect more AKI cases, but also provides the better predictive ability for sixty day mortality [26] (Figure 1).

In clinical practice, it is very common that baseline outpatient SCr is unavailable [30]. While the Acute Dialysis Quality Initiative (ADQI) has recommended backward estimation of baseline SCr by applying the Modification of Diet in Renal Disease (MDRD) formula, making the assumption of an estimated GFR value of 75 mL/min/1.73 m² (ScrGFR-75) for patients with no available baseline SCr [24], the European Renal Best Practice (ERBP) proposes the usage of the initial documented SCr value on hospital admission (SCrADM) as the baseline SCr when baseline outpatient SCr values are not available [31].
The types of strategies have their own shortcomings [24,31]. While backward calculation can lead to misclassification of AKI, especially in the early stages [32], the use of SCrADM as the baseline SCr can be inaccurate in patients who might be suffering from community-acquired AKI, as the SCr might have already escalated before the time of hospitalization [30,33]. In addition, using SCrGFR-75 as surrogate for baseline SCr was established to be more sensitive but less specific for AKI diagnosis compared with using SCrADM [30].

In clinical practice, prevention of AKI and subsequent timely treatment may improve the outcomes of the patient with AKI. Therefore, for the stratification risk purposes within the clinical undertakings, we highly encourage the application of SCrGFR-75 for the diagnosis of AKI, as it has the ability to properly identify more AKI cases. On the other hand, using SCrADM may be suitable for research studies, as it would be more likely to enroll patients who are going to benefit from the intervention [30]. Furthermore, since GFR decreases with age, the use of SCrGFR-75 might result in over-AKI classification in the elderly [34], therefore use of a different assumed GFR for SCr estimation could be considered in different age groups. For instance, applying SCrGFR-70 among the elderly and SCrGFR-100 for the younger adult would generate high amount of sensitivity together with specificity [30,34].
Among perioperative and intensive care unit (ICU) settings, volume overload is very common. It can cause the dilution and masking SCr increments, which may result in a delay in AKI diagnosis in critically ill patients [35]. Adjust SCr for fluid balance has been proposed with the following formula: adjusted SCr = SCr × correction factor, when correction factor = 1 + [cumulative fluid balance (L)/(admission body weight (kg) × 0.6)] [35–37]. SCr adjustment for fluid balance can provide a more accurate detection of AKI cases in critically ill patients and increases predictive ability of sixty day mortality [35].

Given the definition of AKI is currently based on absolute or relative changes in SCr and weight-adjusted hourly urine output [23], body weight (BW) is an essential factor and used when normalizing the UO for weight and time. Using actual BW to diagnose and stage AKI by UO criterion is more sensitive and less specific than ideal BW [38]. Thus, the choice of using ABW or IBW for AKI diagnosis and classification depends on the purpose of the AKI definition. In clinical practice, AKI prevention and early treatment of AKI may help improve patient outcomes. Therefore, for screening purposes in clinical practice, we suggest the use of ABW to normalize UO for AKI diagnosis, as it can potentially identify more patients with AKI earlier. Conversely, for research studies, using IBW may be more appropriate, as it is likely to select patients who are going to benefit the treatment [38].

2.3. Persistent AKI and Renal Recovery after AKI

Recently, the term “persistent AKI (pAKI)” has been proposed and is described as AKI diagnosis together with an increase in SCr that persisted through hospital discharge [39–45]. pAKI could be highly relevant endpoint for some additional further studies in the future [39]. As AKI which resolve very rapidly still has worse outcomes when compared to the patients who are not suffering from AKI, the overall outcome of transient AKI had been reported to be significantly better when comparison is made to pAKI [39–45]. pAKI is closely linked with more severe outcomes among patients when comparison is made to transient AKI, such as development of progressive CKD, increased mortality among those hospitalized, and reduced long-term survival [39–45].

The effects of renal recovery following AKI condition on the outcomes have recently been described [39,46,47], when complete renal recovery is defined as no AKI at patient discharge (comparing the SCr at discharge to the SCr at baseline). On the other hand, partial renal recovery is defined as AKI that is not complete renal recovery, and without the need for renal replacement therapy at discharge. No renal recovery is defined as a need for renal replacement therapy at discharge [39,46,47].

The Acute Disease Quality Initiative 16 Workgroup recently published a consensus report that placed more emphasis on the importance of renal recovery following AKI [46]. Recovery of renal function after AKI has been shown to be an independent determinant of morbidity and mortality in patients who are hospitalized, including those who are within ICU, or those who had undergone a process of cardiac surgery [40,48–50].

3. Causes and Diagnosis of AKI

The main causes of AKI are divided into three categories: prerenal, intrinsic renal and postrenal (Figure 2).
Figure 2. Causes of AKI.

AKI can have many different causes as shown in Figure 2, such as decreased kidney perfusion, parenchymal kidney diseases, acute tubular necrosis (ATN), and obstruction of the urinary tract. Articles on detailed specific causes of AKI have been published in our current special issue "Diagnostics, Risk Factors, Treatment and Outcomes of Acute Kidney Injury in a New Paradigm"(https://www.mdpi.com/journal/jcm/special_issues/acute_kidney_injury) [3,51-88]. Reported incidence of AKI is different among different patient populations as shown in Table 2.

Table 2. Reported incidence of AKI is different among different patient populations [6-11,59,65,70,72,89-104].

| Patient Populations/Settings | Incidence of AKI |
|-----------------------------|------------------|
| General hospitalized patients | 10%-20% |
| ICU | 20%-50% |
| Cardiac surgery | 30%-50% |
| Transcatheter Aortic Valve Replacement | 28% |
| Sepsis | 16%-25% |
| Acute respiratory distress syndrome | 44%-50% |
| Extracorporeal Membrane Oxygenation | 63% |
| AKI | 45% |
| Severe AKI requiring RRT | 41% |
| Liver transplantation | 8% |
| AKI | 41% |
| Severe AKI requiring RRT | 8% |
AKI, acute kidney injury; ICU, intensive care unit; RRT, renal replacement therapy.

In patients with AKI from some other causes, urinalysis, dipstick, sediment, albuminuria and total proteinuria; and the presence or absence of hematuria, pyuria, renal tubular epithelial cells, and granular and cellular casts, chemistries, and serologic evaluation can be helpful in identifying the cause of AKI, as shown in Table 3. Imaging studies are usually performed to evaluate the presence of hydronephrosis, defined as dilatation of the renal collecting system due to obstruction [1].

Table 3. Diagnostic tests in patients with AKI [1,105,106].

| Diagnostic test                  | Findings                                      | Pathologic Condition(s)                      |
|----------------------------------|-----------------------------------------------|----------------------------------------------|
| Urinalysis with                  | Hyaline cast                                  | Prerenal azotemia                            |
| microscopy                       | Muddy brown cast                              | ATN                                          |
|                                  | Dysmorphic RBC & RBC casts                    | GN                                           |
|                                  | WBC casts                                     | AIN                                          |
|                                  | Crystals                                      | Crystal induced nephropathy, drugs, nephrolithiasis |
|                                  | Monomorph RBCs, WBCs                          | UTI, Nephrolithiasis, Genitourinary tumors etc |
|                                  | Protein                                       | GN, Monoclonal gammopathy                     |
| CBC with peripheral smear        | Anemia, Schistocytes, low platelets           | TMA                                          |
| Urinary osmolality               | Osmolar gap & severe metabolic acidosis       | Toxin                                        |
| Creatinine kinase                | >5000 IU/L                                    | Rhabdomyolysis                               |
| Serologic tests                  | HIV antibody                                  | HIV associated nephropathy, HIV induced immunocomplex kidney disease |
|                                  | Hepatitis serology                            | Membranous GN, MPGN                          |
|                                  | ANA, dsDNA                                    | Lupus nephritis                              |
|                                  | C-ANCA, P-ANCA                                | ANCA vasculitis                              |
|                                  | Rheumatoid factor,                            | Cryoglobulinemia, MPGN                       |
|                                  | Cryoglobulins                                 |                                              |
|                                  | Anti–GBM antibody                             | Good pasture syndrome                        |
|                                  | ASO                                           | Infection related GN                         |
| Low complement levels            | Lupus, Infection related GN, atheroemboli, MPGN, shunt nephritis |
| Fractional excretion of sodium   | <1%                                           | Prerenal azotemia                            |
| (FeNa) *                         |                                               |                                              |
| Fractional excretion of          | <35%                                          | Prerenal azotemia                            |
| urea (Fe Urea)                   |                                               |                                              |
| POCUS (Volume Assessment)        | IVC diameter ↓ (>50% w/inspiration)           | Hypovolemia                                  |
| Renal USG                        | Hydronephrosis, Hydroureter                   | Nephrolithiasis, Retropertoneal fibrosis, BPH, Phimosis, Ureteral obstruction |
| Renal vein thrombosis            |                                              | Hypercoagulable state                        |
| Renal biopsy                     | Variable                                      | GN, ATN, AIN, crystal induced nephropathy    |
| Newer biomarkers                 | ↑NGAL, KIM 1, (TIMP-2)-(IGFBP7) **            | "Damage biomarkers” increased much before rise in creatinine |
ATN: Acute tubular necrosis, GN- Glomerulonephritis, AIN: Acute interstitial nephritis, UTI: Urinary tract infection, ANA: Antinuclear antibody, ANCA: Antinuclear cytoplasmic antibody, GBM: Glomerular basement membrane, MPGN: Membranoproliferative glomerulonephritis, ASO: Anti Streptolysin, POCUS: Point of care ultrasound, IVC: Inferior vena cava, NGAL: neutrophil gelatinase-associated lipocalin, KIM-1: Kidney injury molecule -1, TIMP 2: Tissue inhibitor of metalloproteinases-2, IGFBP7: Insulin like growth factor-binding protein 7. Notes: UA dipstick ++ for blood but no RBCs - Suspect rhabdomyolysis. If urine protein creatinine ratio quite elevated but urine dipstick with low grade proteinuria - Suspect multiple myeloma. BUN out of proportion to Cr - Suspect GI bleeding, high dose steroids, high protein feeding. Urine eosinophils have low sensitivity (30.8%) and specificity (68.2%) for AIN so not diagnostic of AIN. * FeNa is affected in CKD, diuretics, contrast administration, acute GN and Rhabdomyolysis so is not quite reliable in cause of AKI diagnosis. ** FDA approved in 2014.

Furosemide “stress test” (administration of 1 mg/kg of IV furosemide with 1:1 replacement of urine output with saline) can be used to assess prognosis: Patients with <200 mL of urine output over the subsequent 2 h are at greater risk for progression to a higher AKI stage or to the need for RRT [107,108].

4. Biomarkers of Acute Kidney Injury (AKI)

SCr level does not detect AKI promptly and increased SCr and oliguria may not occur for several hours after the onset of an acute decline in GFR [1]. In addition, the rise in SCr (and decrease in estimated GFR) may be delayed in patients with low muscle mass or volume overload and faster in those with high muscle mass or volume depletion [1,109].

Within the last few years, the discovery and further validation of the special biomarkers of the kidney injury has attracted great attention [110]. Several biomarkers like Cystatin C and further neutrophil gelatinase-associated lipocalin have consequently been recommended for the purpose of diagnosis, severity grouping and more essential, the modification in the AKI outcome [1]. Novel biomarkers are under investigation to determine whether they may enable earlier detection of decreased GFR and complications of AKI [3,111], as shown in Table 4.

Table 4. Characteristics of selected novel biomarkers for acute kidney injury [112–127].

| Novel Biomarkers | Specimen          | Type            | Representation                              | Study Population                  |
|------------------|-------------------|-----------------|--------------------------------------------|-----------------------------------|
| NGAL             | Serum, urine      | Upregulated protein | Distal tubules                             | Cardiac surgery, Critically ill, CRS, KT |
| KIM-1            | Urine             | Upregulated protein | Proximal tubules                           | Cardiac surgery, KT               |
| L-FABP           | Urine             | Upregulated protein | Proximal tubules                           | Cardiac surgery, Critically ill    |
| IL-10            | Urine             | Cytokine         | Inflammatory cascades                      | Cardiac surgery                    |
| IL-18            | Urine             | Cytokine         | Inflammatory cascades                      | Cardiac surgery, Critically ill, KT|
| Urine Cystatin C | Serum, urine      | Functional       | Proximal tubules (urine), glomerular (serum)| Critically ill                     |
| NAG              | Urine             | Enzyme           | Proximal tubules                           | Critically ill                     |
| IGFBP7           | Urine             | Upregulated protein | Proximal tubules                           | Critically ill, cardiac surgery    |
| TIMP-2           | Urine             | Upregulated protein | Proximal tubules                           | Critically ill, cardiac surgery    |
| Calprotectin     | Urine             | Upregulated protein | Renal inflammation                        | Hospitalized patients              |
| AGT              | Urine             | Enzyme           | Renin-angiotensin activation               | Heart failure                      |
| microRNA         | Urine             | RNA fragment     | Proximal and distal tubules                | Cardiac surgery                    |

AGT, angiotensinogen; CRS, cardiorenal syndrome; IGFBP, insulin-like growth factor-bind protein 7; IL, interleukin; KIM-1, Kidney injury molecule-1; KT, kidney transplantation; L-FABP, liver fatty
acid; LMWP, low-molecular weight protein; NAG, N-acetyl-b-D-glucosaminidase; NGAL, neutrophil gelatinase-associated lipocalin; TIMP-2, tissue inhibitor of metalloproteinase 2.

5. Risk Factors

While diabetics with baseline CKD represent the highest risk patient population for AKI development [128], overall reported risk factors for AKI from the literature include older age, history of diabetes, hypertension, congestive heart failure, peripheral vascular disease, sepsis, use of nephrotoxic drugs, higher severity of disease scores, use of vasopressors/inotropes, high risk surgery, emergency surgery, hemodynamic instability, use of intra-aortic balloon pump, anemia requiring blood transfusion, and longer time in cardiopulmonary bypass pump [129–132], Table 5.

| Modifiable                                      | Non-Modifiable                             |
|------------------------------------------------|---------------------------------------------|
| • Anemia/Blood transfusion                     | • Chronic kidney disease                    |
| • Hypertension                                 | • Chronic liver disease                     |
| • Hypercholesterolemia                         | • Congestive heart failure                  |
| • Hypoalbuminemia                              | • Diabetes mellitus                         |
| • Infection/Sepsis                             | • Older age                                 |
| • Mechanical ventilator                        | • Peripheral vascular disease               |
| • Nephrotoxic agents                           |                                            |
| • Use of vasopressors/inotropes                |                                            |
| • High risk surgery                            |                                            |
| • Emergency surgery                            |                                            |
| • Hemodynamic instability                      |                                            |
| • Use of intra-aortic balloon pump             |                                            |
| • Longer time in cardiopulmonary bypass pump   |                                            |

6. Outcomes and Mortality Risk among Patients with AKI

AKI is associated with significant morbidity and mortality [13–15]. Patients with AKI who fail to recover their renal function, have been reported to be having 47% hospital mortality. In addition, among those who are discharged from the hospital alive, 1-year patient survival is only 77% [47]. Mortality risk among patients with AKI in different patient populations are demonstrated in Table 6. In addition to increased mortality, AKI is also associated with an increased risk of cardiovascular mortality and major cardiovascular events, particularly heart failure and acute myocardial infarction [133].

Irrespective of cause, the severity of AKI is related to the risk for complications [1]. Complications of AKI result from impaired excretory, endocrine, and metabolic kidney functions. Decreased GFR and tubular function lead to retained water and solutes, manifested by volume overload, hyperkalemia, high an- ion gap metabolic acidosis, hyponatremia, hyperphosphatemia, hypermagnesemia, encephalopathy, pericarditis, pruritus, and bleeding due to platelet dysfunction [1]. Drug toxicity is common because of altered pharmacokinetics and pharmacodynamics. Complications may occur in other organ systems throughout the course of disease; multiple organ failure is associated with the highest mortality. Such form of injuries are mainly recorded in close to 20% of the patients who have been hospitalized, with the great complications recorded to comprise of drug toxicity, uremic complications, disorders of the electrolyte and subsequently volume overload. Incomplete recovery may lead to new onset or worsening of CKD [1].

| Patient Populations       | Odds Ratio (95% CI) for Mortality |
|---------------------------|-----------------------------------|
| Acute coronary syndrome   | 4.1 (3.3–5.0)                     |
| Cardiac surgery           | 6.27 (3.6–11.0)                   |
| TAVR                      | 18.0 (6.3–52.0)                   |
| ECMO                      | 3.7 (2.9–4.9)                     |
| Liver transplantation     | 3.0 (2.3–3.8)                     |
Cirrhosis: 2.6 (1.5–4.7)
Lung transplantation: 1.5 (1.1–1.9)
Stem cell transplantation: 3.0 (2.1–4.5)
Heart transplantation: 2.7 (1.6–3.3)
Critically ill patients: 1.4 to 2.5
Rhabdomyolysis: 3.3 (1.1–9.7)
Cardiorenal syndrome: 4.9 (3.7–6.5)
Burn patients: 11.3 (7.3–17.4)
Ischemic stroke: 2.5 (1.5–4.1)
Cancer: 3.0 (2.3–3.9)
COPD: 1.8 (1.6–2.0)
Malnutrition: 2.0 (1.5–2.7)
Gastrointestinal bleeding: 2.6 to 4.9

COPD, chronic obstructive pulmonary disease; ECMO, extra-corporal membrane oxygenation; NSAID, non-steroidal anti-inflammatory disease; TAVR, transcatheter aortic valve.

7. AKI Prevention and Management of AKI

7.1. AKI Prevention

Since severe AKI is associated with a high mortality rate and there are currently no effective targeted pharmacotherapies available for AKI, all the relevant measures that are undertaken for the purpose of preventing AKI (Table 7).

| General Measures |
|------------------|
| Identify patients at risk | - Personal risks: older age, history of CKD, diabetes, dementia, coronary artery disease.  
- Related to clinical scenario: reason for admission, severity of illness, ICU stay, and recurrent hospitalizations. |

| Use of Clinical decision support systems (CDSS) | - Electronic-based alert systems in the hospitals have shown to improve the detection of AKI. |

| Maintain euvolemia | - Use intravenous fluids if hypovolemia is anticipated in clinical settings such as poor oral intake, vomiting, diarrhea, polyuria, etc.  
- Avoid starches for volume resuscitation  
- Avoid volume overload by discontinuing fluids when appropriate. |

| Avoid nephrotoxic medications. | - Discontinue medications such as NSAIDs  
- Avoid ACE/ARB inhibitors (controversial) which affect the hemodynamics of the kidneys.  
- Avoid nephrotoxic antibiotics such as aminoglycosides, amphotericin and vancomycin. If their use is necessary, monitor levels if appropriate.  
- Utilize minimal dose and for the shortest time possible. |

| Judicious use of contrasted studies | - Outweigh risks vs. benefits of contrasted studies. Intra-arterial pose a higher risk than intravenous contrasted studies. |
Avoid hypotension

- Decrease in renal blood flow is a known risk factor for AKI. It is therefore imperative to keep MAP >65 (target 65–70 mmHg), and a higher target (80-85 mmHg) in chronically hypertensive patients.
- If vasopressors are too be used in the ICU, norepinephrine should be the first-choice to protect kidney function.

Renal function monitoring

- Monitor SCr as often as necessary, depending on the risk factors and clinical scenario.
- Monitor fluid input and urinary output.

Specific Clinical Scenarios

Patients undergoing a procedure needing IV contrast use

- Discontinue nephrotoxic medications
- IV hydration with intravenous isotonic saline at a rate of 1 to 1.5 ml per kilogram per hour for 12 h before and up to 24 h after the procedure. A shorter protocol for patients undergoing urgent procedures comprises an intravenous infusion of isotonic saline for 1 to 3 h before and 6 h after the procedure.
- Recent data does not support the use of IV bicarbonate or N-acetyl cysteine.
- Utilize low-osmolar or iso-osmolar contrast media.
- Minimize contrast volume (<350 ml or <4 ml per kilogram).

Traumatic and non-traumatic rhabdomyolysis

- Early and aggressive volume expansion with isotonic solutions aimed at increasing urine flow (about 200–300 mL/h).
- Use of bicarbonate is not evidence based and might precipitate metastatic tissue calcification and ionized hypocalcemia
- Use of diuretics is not generally recommended.

Patients undergoing cardiac surgery

Preoperative:
- Perform pre-operative AKI stratification.
- Delay elective surgeries if current AKI and delay 24–72 h after contrast use.
- Discontinue ACE/ARB (controversial)
- Discontinue NSAIDs.
- Limited use of blood transfusions.
- Correcting hypoalbuminemia with exogenous albumin preoperatively may play a role in preventing AKI.
- Use of balanced crystalloid solutions guided by measures of fluid responsiveness.

Intraoperative
- Cold perfusion of the kidneys during aortic aneurysm repair
- Avoidance of hyperthermia.
- Pulsatile Cardiopulmonary bypass.
- Avoidance of hemodilution.
- Use of volatile anesthetics.
- Minimization of aortic manipulation.
- Techniques to prevent procedure-related atheroembolism.

Postoperative
- Low tidal volume strategy.
- General measures mentioned above.
- Glucose control (target 127–179 mg/dL).

AKI; acute kidney injury; CKD, chronic kidney disease; ICU, intensive care unit; NSAIDs, nonsteroidal anti-inflammatory drugs; SCr, serum creatinine; ACE, angiotensin converting enzyme; ARB, angiotensin-receptor blocker; MAP, mean arterial pressure; IV, intravenous.

Fluid composition has also been the subject of substantial investigation. The use of hydroxyethyl starch has been shown to result in increased rates of AKI especially in patients with sepsis [151,152], while on the other hand, saline has been demonstrated to increase the risks associated with dialysis, mortality and continuous renal dysfunction when compared to the fluids that are very similar to the relevant physiological ones like the Ringer’s lactate solution [153,154].

General measures undertaken to limit the risk comprises of the prevention as well as the treatment of volume depletion and avoidance of nephrotoxic drugs [155]. IV isotonic fluids before,
during, and after intra-arterial administration of iodinated radiocontrast media may reduce risk for contrast-induced AKI [98,156–158]. Monitoring therapeutic levels of nephrotoxic drugs, such as vancomycin, aminoglycosides, and calcineurin inhibitors, can reduce risk for AKI. KDIGO suggests additional measures to reduce the risk for nephrotoxicity of aminoglycosides and amphotericin B [1].

While the data on discontinuation of the continued angiotensin-converting enzyme inhibitors (ACEIs) as well as the angiotensin-receptor blockers (ARBs) during the period of acute illness to prevent AKI is controversial [159,160], some other nephrotoxic drugs need to be avoided especially among people who are suffering from CKD, such as nonsteroidal anti-inflammatory drugs (NSAIDs) [161]. Contrast-associated AKI is becoming less frequent because of reduced toxicity and lesser amounts of contrast media used for imaging techniques. However, prevention measures should still be considered for individual patients, especially in patients with CKD [2].

7.2. Management of AKI

The timely identification of the at risk patents, timely diagnosis and early treatment of all the AKI cases are essential part of the general management of individual patients who might be suffering from AKI. The initial principle of AKI management is specifically to treat its causative factor or trigger, such as treating infection in sepsis-associated AKI. The second principle of management and specific treatments according to the underlying cause of AKI syndromes such as hepatorenal syndrome, cardiorenal syndrome, glomerulonephritis, interstitial nephritis, vasculitis, and multiple myeloma, etc. Currently, there are currently no effective pharmacotherapies for treating ATN. The specific treatments for these specific types of kidney injuries are not focus of this review. The third principle is based on ensuring that there is avoidance of any additional insults of AKI. There is need to optimize hemodynamics that are systemic based, so that even in the absence of some other triggers, additional damage is not experienced and correct perfusion pressure and renal perfusion are adequately maintained. The fourth principle is to apply provide supportive care to prevent and treat complications.

RRT are a spectrum of dialysis modalities employed in management of renal dysfunction. They are broadly classified as continuous, intermittent and hybrid variants. Continuous renal replacement therapies (CRRT) are ideally used in hemodynamically unstable patients to allow steady solute and volume shifts. CRRT further categorized based on principles of clearances [162] to four types. Slow continuous ultra-filtration (SCUF) aims at filtration of plasma water in patients with refractory volume overload while no significant solute clearances are achieved. The other three modalities are continuous veno-venous hemofiltration (CVVH) (convection), continuous veno-venous hemodialysis (CVVHD) (diffusion) and continuous veno-venous hemodiafiltration (CVVHDF) (diffusion and convection) [163–166]. Peritoneal dialysis, a slow efficient continuous modality is an acceptable alternative to extra corporeal modalities [167]. Intermittent hemodialysis (IHD) is routinely prescribed for 3 to 4 h three times a week and supports rapid clearances of small molecules and toxic drugs [168]. Hybrid therapies include sustained low-efficiency dialysis (SLED), prolonged intermittent renal replacement therapy (PIRRT), extended daily dialysis with filtration (EDDF) and accelerated veno-venous hemofiltration (AVVH) [169]. Hybrid modalities tend to blend features of intermittent and continuous modalities with objectives to enhance hemodynamic stability while minimizing the disadvantages of continues modalities [170].

Even though CRRT has multiple potential advantages, no randomized control studies (RCT) have proven survival benefit of any specific modality [171,172]. In a metaanalysis by Nash et al. including 21 studies comparing iHD, SLED and CRRT modalities failed to demonstrate mortality difference or superior renal recovery of one over other groups [173]. Friedrich et al. performed a systematic review involving 19 RCTS, compared outcomes among hemofiltration and hemodialysis in patients with AKI and were unsuccessful in achieving survival advantages of one therapy over other. However, hemofiltration group had a trend towards increased clearance of inflammatory molecules including cytokines [174].
Currently, recommended effluent CRRT dose for clinical practices is 20 to 25 mL/kg/hr. Multiple studies were conducted comparing different doses. The prospective randomized study by Ronco et al. involving critically ill AKI patients comparing three different doses (20 mL/kg/h, 35 mL/kg/h and 45 mL/kg/h) reported inferior survival rates in in lower dose group (20 mL/kg/hr) compared to higher (35 mL/kg/h and 45 mL/kg/h) [175]. However, the land mark RCTs, VA/NIH Acute Renal Failure Trial Network (ATN trial) [176] by Palevsky et al. (35 mL/kg/h vs. 20 mL/kg/h) and RENAL study by Bellamo et al. (40 mL/kg/hr vs. 25 mL/kg/hr) [177] were ineffective in decreasing mortality, or improving renal recovery at higher dose compared to lower. In a metaanalysis by Clark et al, including 4 RCTs comparing high volume hemofiltration (> 50 mL/kg/hr) (HVHF) to standard volume hemofiltration (SVHF) among septic AKI patients did not demonstrate any difference in 28-day mortality. Even though vasopressor requirements were lower among HVHF group, they sustained significant adverse effects including hypokalemia, hypophosphatemia, metabolic alkalosis, excessive micronutrient loss [178].

Significant controversies exist regarding the timing of initiation of RRT and are still a topic of debate. HEROICS study, a prospective randomized multicenter trial including post-cardiac surgery septic shock patients compared early HVHF (80 mL/kg/h) to delayed CVVHDF with no difference in outcomes (30 day mortality) [179]. The Artificial Kidney Initiation In Kidney Injury (AKIKI) trial and Initiation of Dialysis Early Versus Delayed in the Intensive Care Unit (IDEAL- ICU) trials are randomized multicenter studies involving critically ill AKI patients with KDIGO stage3 compared early (Immediately after randomization or within 12 h) vs. delayed initiation of RRT, (refractory to medical management or >48 h) were unsuccessful in demonstrating outcome benefits in early group as compared to delayed [180,181]. The Effect of Early vs. Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients with Acute Kidney Injury (ELAIN) study did report a 15 % reduction in 90-day mortality in early initiation group, however this study suffered serious criticism including single centered study with significant number of post cardiac surgical patients, RRT initiation at KDIGO stage 2 and less than 24 h difference in initiation of RRT among both groups [182].The current evidence suggests no tremendous benefit of early initiation of RRT but is associated with complications. Therefore, the timing of initiation of RRT should be individualized based on judicious examination, disease acuity and medical necessity [183]. The two large ongoing multicenter RCTS, AKIKI-2 [184] and START- AKI [185] trials might further shed some light on Ideal timing of RRT.

8. Potential Directions and Future Scope

Two advances from past decades, the usage of the computer decision intelligence and the discovery of AKI biomarkers, have the great ability to generally improve the approach applied in diagnosis and further treatment of AKI. For instance, in the instance of AKI, electronic, the automated diagnostic strategy tend to create great opportunity to initiate predictive strategies, subsequently optimize the relevant AKI alerts, and subsequently trace AKI events across various associations, as well as the relevant managerial datasets [186]. In addition, dynamic and multidimensional approach to AKI, using AKI biomarkers over time, will be presented as a versatile theoretic construct usable to characterize and phenotype AKI itself, refining the precision of diagnosis and making possible the ability to track different aspects of the injury as they change over time, potentially leading to a modern and personalized approach to AKI [187] (Figure 3).
9. Conclusions

Based on the mere fact that presently there is absence of effective pharmacotherapies that are usable for AKI, all measures geared toward preventing the condition should be taken seriously. Two advances from past decades, the usage of computer decision intelligence support and the discovery of AKI biomarkers, have the great ability to in a sustainable way improve the general diagnostic strategy to AKI and its further treatment. The advances in developments and future progress in AKI biomarkers over time can lead to future of precision and personalized approach to AKI management.

Author Contributions: C.T., P.H. and W.C conducted the literature search. W.K., K.K., P.H., S.R.K. contributed to the outlines of the study and collected the information. C.T., P.H., and W.C drafted the manuscript. All authors gave comments on the earlier versions of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: We do not have any financial or non-financial potential conflicts of interest.

References

1. Levey, A.S.; James, M.T. Acute Kidney Injury. Ann. Intern. Med. 2017, 167, ITC66–ITC80.
2. Ronco, C.; Bellomo, R.; Kellum, J.A. Acute kidney injury. Lancet 2019, 394, 1949–1964.
3. Gameiro, J.; Agapito Fonseca, J.; Jorge, S.; Lopes, J.A. Acute Kidney Injury Definition and Diagnosis: A Narrative Review. J. Clin. Med. 2018, 7, 307.
4. Jadlowiec, C.; Smith, M.; Neville, M.; Mao, S.; Abdelwahab, D.; Reddy, K.; Moss, A.; Aqel, B.; Taner, T. Acute Kidney Injury Patterns Following Transplantation of Steatotic Liver Allografts. J. Clin. Med. 2020, 9, 954.
5. Manohar, S.; Kompotiatis, P.; Thongprayoon, C.; Cheungpasitporn, W.; Herrmann, J.; Herrmann, S.M. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: Meta-analysis. Nephrol. Dial. Transplant. 2019, 34, 108–117.
6. Thongprayoon, C.; Cheungpasitporn, W.; Mao, M.A.; Sakhuja, A.; Erickson, S.B. Admission hyperphosphatemia increases the risk of acute kidney injury in hospitalized patients. J. Nephrol. 2018, 31, 241–247.
7. Thongprayoon, C.; Cheungpasitporn, W.; Mao, M.A.; Sakhuja, A.; Kashani, K. U-shape association of serum albumin level and acute kidney injury risk in hospitalized patients. *PLoS ONE* **2018**, *13*, e0199153.

8. Thongprayoon, C.; Cheungpasitporn, W.; Mao, M.A.; Harrison, A.M.; Erickson, S.B. Elevated admission serum calcium phosphate product as an independent risk factor for acute kidney injury in hospitalized patients. *Hosp. Pract.* **2019**, *47*, 73–79.

9. Thongprayoon, C.; Cheungpasitporn, W.; Mao, M.A.; Sakhuja, A.; Erickson, S.B. Admission calcium levels and risk of acute kidney injury in hospitalised patients. *Int. J. Clin. Pract.* **2018**, *72*, e13057.

10. Cheungpasitporn, W.; Thongprayoon, C.; Harrison, A.M.; Erickson, S.B. Admission hyperuricemia increases the risk of acute kidney injury in hospitalized patients. *Clin. Kidney J.* **2016**, *9*, 51–56.

11. Cheungpasitporn, W.; Thongprayoon, C.; Erickson, S.B. Admission hypomagnesemia and hypermagnesemia increase the risk of acute kidney injury. *Ren Fail.* **2015**, *37*, 1175–1179.

12. Li, P.K.; Burdmann, E.A.; Mehta, R.L. Acute kidney injury: Global health alert. *Kidney Int.* **2013**, *83*, 372–376.

13. Cerdá, J.; Liu, K.D.; Cruz, D.N.; Jaber, B.L.; Koyner, J.L.; Heung, M.; Okusa, M.D.; Faukel, S. Promoting Kidney Function Recovery in Patients with AKI Requiring RRT. *Clin. J. Am. Soc. Nephrol.* **2015**, *10*, 1859–1867.

14. Silver, S.A.; Long, J.; Zheng, Y.; Chertow, G.M. Cost of Acute Kidney Injury in Hospitalized Patients. *J. Hosp. Med.* **2017**, *12*, 70–76.

15. Hansrivijit, P.; Lertjitbanjong, P.; Thongprason, C.; Cheungpasitporn, W.; Aeddula, N.R.; Salim, S.A.; Chewcharat, A.; Watthanasuntorn, K.; Srivali, N.; Mao, M.A.; et al. Acute Kidney Injury in Pediatric Patients on Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-analysis. *Medicines* **2019**, *6*, 109.

16. Thongprayoon, C.; Cheungpasitporn, W.; Shah, I.K.; Kashyap, R.; Park, S.J.; Kashani, K. Long-term Outcomes and Prognostic Factors for Patients Requiring Renal Replacement Therapy After Cardiac Surgery. *Mayo Clin. Proc.* **2015**, *90*, 857–864.

17. Silver, S.A.; Chertow, G.M. The Economic Consequences of Acute Kidney Injury. *Nephron* **2017**, *137*, 297–301.

18. Selby, N.M.; Kolhe, N.V.; McIntyre, C.W.; Monaghan, J.; Lawson, N.; Elliott, D.; Packington, R.; Fluck, R.J. Defining the cause of death in hospitalised patients with acute kidney injury. *PLoS ONE* **2012**, *7*, e48580.

19. Mehta, R.L.; Cerdá, J.; Burdmann, E.A.; Tonelli, M.; García-Garcia, G.; Jha, V.; Susanitaphong, P.; Rocco, M.; Vanholder, R.; Sever, M.S.; et al. International Society of Nephrology’s 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): A human rights case for nephrology. *Lancet* **2015**, *385*, 2616–2643.

20. Charlton, J.R.; Portilla, D.; Okusa, M.D. A basic science view of acute kidney injury biomarkers. *Nephrol. Dial. Transplant.* **2014**, *29*, 1301–1311.

21. Sutherland, S.M.; Chawla, L.S.; Kane-Gill, S.L.; Hsu, R.K.; Kramer, A.A.; Goldstein, S.L.; Kellum, J.A.; Ronco, C.; Bagshaw, S.M. Utilizing electronic health records to predict acute kidney injury risk and outcomes: Workgroup statements from the 15(th) ADQI Consensus Conference. *Can. J. Kidney Health Dis.* **2016**, *3*, 11.

22. Cheungpasitporn, W.; Kashani, K. Electronic Data Systems and Acute Kidney Injury. *Contrib. Nephrol.* **2016**, *187*, 73–83.

23. Kellum, J.A. KDIGO clinical practice guideline for acute kidney injury, Section 2: AKI Definition. *Kidney Int. Suppl.* **2012**, *2*, 19–36.

24. Bellomo, R.; Ronco, C.; Kellum, J.A.; Mehta, R.L.; Palevsky, P. Acute Dialysis Quality Initiative w. Acute renal failure—Definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit. Care* **2004**, *8*, R204–R212.

25. Mehta, R.L.; Kellum, J.A.; Shah, S.V.; Molitoris, B.A.; Ronco, C.; Warnock, D.G.; Levin, A. Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury. *Crit. Care* **2007**, *11*, R31.

26. Thongprayoon, C.; Cheungpasitporn, W.; Kittanamongkolchai, W.; Srivali, N.; Ungprasert, P.; Kashani, K. Optimum methodology for estimating baseline serum creatinine for the acute kidney injury classification. *Nephrology* **2015**, *20*, 881–886.
27. Acosta-Ochoa, I.; Bustamante-Munguira, J.; Mendiluce-Herrero, A.; Bustamante-Bustamante, J.; Coca-Rojo, A. Impact on Outcomes across KDIGO-2012 AKI Criteria According to Baseline Renal Function. *J. Clin. Med.* 2019, 8, 1323.

28. Siew, E.D.; Ikizler, T.A.; Matheny, M.E.; Shi, Y.; Schildcrout, J.S.; Danciu, I.; Dwyer, J.P.; Srirach, M.; Hung, A.M.; Smith, J.P.; et al. Estimating baseline kidney function in hospitalized patients with impaired kidney function. *Clin. J. Am. Soc. Nephrol.* 2012, 7, 712–719.

29. Siew, E.D.; Matheny, M.E.; Ikizler, T.A.; Lewis, J.B.; Miller, R.A.; Waitman, L.R.; Go, A.S.; Parikh, C.R.; Peterson, J.F. Commonly used surrogates for baseline renal function affect the classification and prognosis of acute kidney injury. *Kidney Int.* 2010, 77, 536–542.

30. Thongprayoon, C.; Cheungpasitporn, W.; Harrison, A.; Kittanamongkolchai, W.; Ungprasert, P.; Srivali, N.; Akhoundi, A.; Kashani, K.B. The comparison of the commonly used surrogates for baseline renal function in acute kidney injury diagnosis and staging. *BMC Nephrol.* 2016, 17, 6.

31. Ad-hoc working group of ERBP; Fliser, D.; Laville, M.; Covic, A.; Fouque, D.; Vanholder, R.; Juillard, L.; Van Biesen, W. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: Part 1: Definitions, conservative management and contrast-induced nephropathy. *Nephrol. Dial. Transplant.* 2012, 27, 4263–4272.

32. Pickering, J.W.; Endre, Z.H. Back-calculating baseline creatinine with MDRD misclassifies acute kidney injury in the intensive care unit. *Clin. J. Am. Soc. Nephrol.* 2010, 5, 1165–1173.

33. Hsu, C.Y.; Ordoñez, J.D.; Chertow, G.M.; Fan, D.; McCulloch, C.E.; Go, A.S. The risk of acute renal failure in patients with chronic kidney disease. *Kidney Int.* 2008, 74, 101–107.

34. Spoorenberg, S.M.; Meijvis, S.C.; Navis, G.; Bos, W.J. Age- and gender-adjusted eGFR to estimate baseline creatinine for RIFLE criteria. *NDT Plus.* 2011, 4, 365–366.

35. Thongprayoon, C.; Cheungpasitporn, W.; Srivali, N.; Ungprasert, P.; Kittanamongkolchai, W.; Kashani, K. The impact of fluid balance on diagnosis, staging and prediction of mortality in critically ill patients with acute kidney injury. *J. Nephrol.* 2016, 29, 221–227.

36. Liu, K.D.; Thompson, B.T.; Ancukiewicz, M.; Steingrub, J.S.; Douglas, J.S.; Matthay, M.A.; Wright, P.; Peterson, M.W.; Rock, P.; Hyzy, R.C.; et al. Acute kidney injury in patients with acute lung injury: Impact of fluid accumulation on classification of acute kidney injury and associated outcomes. *Crit. Care Med.* 2011, 39, 2665–2671.

37. Macedo, E.; Bouchard, J.; Soroko, S.H.; Chertow, G.M.; Himmelfarb, J.; Ikizler, T.A.; Paganini, E.P.; Mehta, R.L. Fluid accumulation, recognition and staging of acute kidney injury in critically-ill patients. *Crit. Care* 2010, 14, R82.

38. Thongprayoon, C.; Cheungpasitporn, W.; Akhoundi, A.; Ahmed, A.H.; Kashani, K.B. Actual versus ideal body weight for acute kidney injury diagnosis and classification in critically ill patients. *BMC Nephrol.* 2014, 15, 176.

39. Kellum, J.A. Persistent Acute Kidney Injury. *Crit. Care Med.* 2015, 43, 1785–1786.

40. Perinel, S.; Vincent, F.; Lautrette, A.; Dellamonica, J.; Mariat, C.; Zeni, F.; Cohen, Y.; Tardy, B.; Souweine, B.; Darmon, M. Transient and Persistent Acute Kidney Injury and the Risk of Hospital Mortality in Critically Ill Patients: Results of a Multicenter Cohort Study. *Crit. Care Med.* 2015, 43, e269–e275.

41. Thongprayoon, C.; Cheungpasitporn, W.; Mao, M.A.; Srivali, N.; Kittanamongkolchai, W.; Harrison, A.; Greason, K.L.; Kashani, K.B. Persistent acute kidney injury following transcatheter aortic valve replacement. *J. Card. Surg.* 2017, 32, 550–555.

42. Goldberg, A.; Kogan, E.; Hammerman, H.; Markiewicz, W.; Aronson, D. The impact of transient and persistent acute kidney injury on long-term outcomes after acute myocardial infarction. *Kidney Int.* 2009, 76, 900–906.

43. Choi, J.S.; A Kim, Y.; Kim, M.J.; Kang, Y.U.; Kim, C.S.; Bae, E.H.; Ma, S.K.; Ahn, Y.; Jeong, M.H.; Kim, S.W. Relation between transient or persistent acute kidney injury and long-term mortality in patients with myocardial infarction. *Am. J. Cardiol.* 2013, 112, 41–45.

44. Wi, J.; Ko, Y.G.; Kim, J.S.; Kim, B.K.; Choi, D.; Ha, J.W.; et al. Impact of contrast-induced acute kidney injury with transient or persistent renal dysfunction on long-term outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention. *Heart* 2011, 97, 1753–1757.
Contrast Med

Reduce the Incidence of Acute Kidney Injury in Patients Undergoing Emergency Laparotomy?

B.; Doyle, J.; Sarnowski, A.; Saadat, F.; Samuels, T.L.; Huddart, S.; Quiney, N.; Dickinson, M.C.; McCormick, A.; Manfredini, R.; De Giorgi, A.; et al. Acute kidney disease and renal recovery: Consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat. Rev. Nephrol. 2017, 13, 241–257.

Kellum, J.A.; Sileanu, F.E.; Bihorac, A.; Hoste, E.A.; Chawla, L.S. Recovery after Acute Kidney Injury. Am. J. Respir. Crit. Care Med. 2017, 195, 784–791.

Bagshaw, S.M. Epidemiology of renal recovery after acute renal failure. Curr. Opin. Crit. Care 2006, 12, 544–550.

Pannu, N.; James, M.; Hemmelgarn, B.; Klarenbach, S. Association between AKI, recovery of renal function, and long-term outcomes after hospital discharge. Clin. J. Am. Soc. Nephrol. 2013, 8, 194–202.

Swaminathan, M.; Hudson, C.C.; Phillips-Bute, B.G.; Patel, U.D.; Mathew, J.P.; Newman, M.F.; Milano, C.A.; Shaw, A.; Stafford-Smith, M. Impact of early renal recovery on survival after cardiac surgery-associated acute kidney injury. Ann. Thorac. Surg. 2010, 89, 1098–1104.

Wajda, J.; Dumnicka, P.; Sporek, M.; Maziarz, B.; Kolwer, W.; Ząbek-Adamska, A.; Ceranowicz, P.; Kuzniewski, M.; Kusińczak-Cabala, B. Does Beta-Trace Protein (BTP) Outperform Cystatin C as a Diagnostic Marker of Acute Kidney Injury Complicating the Early Phase of Acute Pancreatitis? J. Clin. Med. 2019, 9, 205.

Antal, O.; Ţeşfănescu, E.; Mlesniţ, M.; Bălan, A.M.; Caziuc, A.; Hagău, N. Hemodynamic Predictors for Sepsis-Induced Acute Kidney Injury: A Preliminary Study. J. Clin. Med. 2020, 9, 151.

Lee, K.H.; Sol, I.S.; Park, J.T.; Kim, J.H.; Shin, J.W.; Park, M.; Lee, J.; Kim, Y.H.; Kim, K.W.; Shin, J.I.; et al. Continuous Renal Replacement Therapy (CRRT) in Children and the Specialized CRRT Team: A 14-Year Single-Center Study. J. Clin. Med. 2019, 9, 110.

Lee, C.-C.; Chang, C.-H.; Cheng, Y.-L.; Kuo, G.; Chen, S.-W.; Li, Y.-J.; Chen, Y.; Tian, Y.-C. Diagnostic Performance of Cyclophilin A in Cardiac Surgery-Associated Acute Kidney Injury. J. Clin. Med. 2019, 9, 108.

Rubin, S.; Orieux, A.; Clouzeau, B.; Rigothier, C.; Combe, C.; Gruson, D.; Boyer, A. The Incidence of Chronic Kidney Disease Three years after Non-Severe Acute Kidney Injury in Critically Ill Patients: A Single-Center Cohort Study. J. Clin. Med. 2019, 8, 2215.

Wu, C.-K.; Wu, C.-L.; Su, T.-C.; Kou, Y.R.; Kor, C.-T.; Lee, T.-S.; Tarrng, D.-C. Renal Tubular TRPA1 as a Risk Factor for Recovery of Renal Function from Acute Tubular Necrosis. J. Clin. Med. 2019, 8, 2187.

Averdunk, L.; Fitzner, C.; Levkovich, T.; Leaf; Sobotta, M.; Vielen, J.; Ochi; Moeckel, G.; Marx; Stoppe, C.; et al. Secretory Leukocyte Protease Inhibitor (SLPI)-A Novel Predictive Biomarker of Acute Kidney Injury after Cardiac Surgery: A Prospective Observational Study. J. Clin. Med. 2019, 8, 1931.

Wu, V.C.; Chueh, S.J.; Chang, J.T.; Hsu, B.G.; Ostermann, M.; Chu, T.S. Acute Kidney Injury and Septic Shock-Defined by Updated Sepsis-3 Criteria in Critically Ill Patients. J. Clin. Med. 2019, 8, 1731.

Lerjitbanjong, P.; Thongprayoon, C.; Cheungpasitporn, W.; O’Corragain, O.A.; Srivali, N.; Bathini, T.; Watthanasuntorn, K.; Aedula, N.R.; Salim, S.A.; Ungprasert, P.; et al. Acute Kidney Injury after Lung Transplantation: A Systematic Review and Meta-Analysis. J. Clin. Med. 2019, 8, 1731.

Lee, H.-J.; Bae, J.; Kwon, Y.; Jang, H.S.; Yoo, S.; Jeong, C.W.; Kim, J.-T.; Kim, W.H. General Anesthetic Agents and Renal Function after Nephrectomy. J. Clin. Med. 2019, 8, 1530.

Yoon, H.-K.; Lee, H.-J.; Yoo, S.; Park, S.-K.; Kwon, Y.; Jun, K.; Jeong, C.W.; Kim, W.H. Acute Kidney Injury Adjusted for Parenchymal Mass Reduction and Long-Term Renal Function after Partial Nephrectomy. J. Clin. Med. 2019, 8, 1482.

Fabbian, F.; Savrè, C.; De Giorgi, A.; Cappadona, R.; Simone, D.; Boari, B.; Storari, A.; Gallerani, M.; Manfredini, R.; De Giorgi, A.; et al. Acute Kidney Injury and In-Hospital Mortality: A Retrospective Analysis of a Nationwide Administrative Database of Elderly Subjects in Italy. J. Clin. Med. 2019, 8, 1371.

Doyle, J.; Sarnowski, A.; Saadat, F.; Samuels, T.L.; Huddart, S.; Quiney, N.; Dickinson, M.C.; McCormick, B.; Debrunner, R.; Preece, J.; et al. Does the Implementation of a Quality Improvement Care Bundle Reduce the Incidence of Acute Kidney Injury in Patients Undergoing Emergency Laparotomy? J. Clin. Med. 2019, 8, 1265.

Wu, M.J.; Tsai, S.F.; Lee, C.T.; Wu, C.Y. The Predictive Value of Hyperuricemia on Renal Outcome after Contrast-Enhanced Computerized Tomography. J. Clin. Med. 2019, 8, 1003.
65. Thongprayoon, C.; Cheungpasitporn, W.; Lertjitsanjong, P.; Aeddula, N.R.; Bathini, T.; Watthanasuntorn, K.; Srivati, N.; Mao, M.A.; Kashani, K. Incidence and Impact of Acute Kidney Injury in Patients Receiving Extracorporeal Membrane Oxygenation: A Meta-Analysis. *J. Clin. Med.* 2019, 8, 981.

66. Ortiz-Soriano, V.; Donaldson, K.; Du, G.; Li, Y.; Lambert, J.; Cleland, D.; Thornton, A.; Fanucchi, L.C.; Huaman, M.A.; Neyra, J.A. Incidence and Cost of Acute Kidney Injury in Hospitalized Patients with Infective Endocarditis. *J. Clin. Med.* 2019, 8, 927.

67. Kim, H.-J.; Park, H.-S.; Go, Y.-J.; Koh, W.U.; Kim, H.; Song, J.-G.; Ro, Y.-J. Effect of Anesthetic Technique on the Occurrence of Acute Kidney Injury after Total Knee Arthroplasty. *J. Clin. Med.* 2019, 8, 778.

68. Kim, N.Y.; Hong, J.H.; Koh, D.H.; Lee, J.; Nam, H.J.; Kim, S.Y. Effect of Diabetes Mellitus on Acute Kidney Injury after Minimally Invasive Partial Nephrectomy: A Case-Matched Retrospective Analysis. *J. Clin. Med.* 2019, 8, 468.

69. Oh, T.K.; Song, I.A.; Jeon, Y.T.; Jo, Y.H. Fluctuations in Serum Chloride and Acute Kidney Injury among Critically Ill Patients: A Retrospective Association Study. *J. Clin. Med.* 2019, 8, 447.

70. Thongprayoon, C.; Kaewput, W.; Thamcharoen, N.; Bathini, T.; Watthanasuntorn, K.; Lertjitsanjong, P.; Sharma, K.; Salim, S.A.; Ungprasert, P.; Wijampreecha, K.; et al. Incidence and Impact of Acute Kidney Injury after Liver Transplantation: A Meta-Analysis. *J. Clin. Med.* 2019, 8, 372.

71. Vilander, L.M.; Vaara, S.T.; Kaunisto, M.A.; Pettiiä, V. Common Inflammation-Related Candidate Gene Variants and Acute Kidney Injury in 2647 Critically Ill Finnish Patients. *J. Clin. Med.* 2019, 8, 342.

72. Kaewput, W.; Thongprayoon, C.; Rangsin, R.; Mao, M.A.; Satirapoj, B.; Cheungpasitporn, W. The association between renal function and neurological diseases in type 2 diabetes: A multicenter nationwide cross-sectional study. *Hosp. Pract.* 2019, 47, 46–52.

73. Kim, W.H.; Lee, H.C.; Lim, L.; Ryu, H.G.; Jung, C.W. Intraoperative Oliguria with Decreased SvO2 Predicts Acute Kidney Injury after Living Donor Liver Transplantation. *J. Clin. Med.* 2018, 7, 29.

74. Oh, T.K.; Song, I.A.; Cho, Y.J.; Lim, C.; Jeon, Y.T.; Bae, H.J.; et al. Preadmission Statin Therapy Is Associated with a Lower Incidence of Acute Kidney Injury in Critically Ill Patients: A Retrospective Observational Study. *J. Clin. Med.* 2018, 7, 25.

75. Kim, J.-S.; Kim, Y.J.; Ryoo, S.M.; Sohn, C.H.; Seo, D.W.; Ahn, S.; Lim, K.S.; Kim, W. One–Year Progression and Risk Factors for the Development of Chronic Kidney Disease in Septic Shock Patients with Acute Kidney Injury: A Single-Centre Retrospective Cohort Study. *J. Clin. Med.* 2018, 7, 554.

76. Zelt, J.G.E.; Mielenzuk, L.M.; Liu, P.P.; Dupuis, J.-Y.; Chib, S.; Akbari, A.; Sun, L. Utility of Novel Cardiorenal Biomarkers in the Prediction and Early Detection of Congestive Kidney Injury Following Cardiac Surgery. *J. Clin. Med.* 2018, 7, 540.

77. Marouli, D.; Stylianou, K.; Papadakis, E.; Kroustalakis, N.; Kolyvaki, S.; Papadopoulos, G.; Ioannou, C.; Papaioannou, A.; Daphnis, E.; Georgopoulos, D.; et al. Preoperative Albuminuria and Intraoperative Chloride Load: Predictors of Acute Kidney Injury Following Major Abdominal Surgery. *J. Clin. Med.* 2018, 7, 431.

78. Kee, Y.K.; Kim, D.; Kim, S.-J.; Kang, D.-H.; Choi, K.B.; Oh, H.J.; Ryu, D.-R. Factors Associated with Early Mortality in Critically Ill Patients Following the Initiation of Continuous Renal Replacement Therapy. *J. Clin. Med.* 2018, 7, 334.

79. Lee, H.-C.; Yoon, H.-K.; Nam, K.; Cho, Y.J.; Kim, T.K.; Kim, W.H.; Bahk, J.-H. Derivation and Validation of Machine Learning Approaches to Predict Acute Kidney Injury after Cardiac Surgery. *J. Clin. Med.* 2018, 7, 322.

80. Douvris, A.; Zeid, K.; Hiremath, S.; Brown, P.A.; Sood, M.M.; Arkoub, R.A.; Malhi, G.; Clark, E. Safety Lapses Prior to Initiation of Hemo dialysis for Acute Kidney Injury in Hospitalized Patients: A Patient Safety Initiative. *J. Clin. Med.* 2018, 7, 317.

81. Chen, Y.-Y.; Wu, V.-C.; Huang, W.-C.; Yeh, Y.-C.; Wu, M.-S.; Huang, C.-C.; Wu, M.-S.; Fang, J.-T.; Wu, C.-J.; Nsarf, T.; et al. Norepinephrine Administration Is Associated with Higher Mortality in Dialysis Requiring Acute Kidney Injury Patients with Septic Shock. *J. Clin. Med.* 2018, 7, 274.

82. Shiao, C.-C.; Kan, W.-C.; Wang, J.-J.; Lin, Y.-F.; Chen, L.; Chueh, E.; Huang, Y.-T.; Chiang, W.-P.; Tseng, L.-J.; Wang, C.-H.; et al. Risk of Incident Non-Valvular Atrial Fibrillation after Dialysis-Requiring Acute Kidney Injury. *J. Clin. Med.* 2018, 7, 248.

83. Wu, C.-H.; Chang, H.-M.; Wang, C.-Y.; Chen, L.; Chen, L.W.; Lai, C.-H.; Kuo, S.-W.; Wang, H.-C.; Wu, V.-C. Long-Term Outcomes in Patients with Incident Chronic Obstructive Pulmonary Disease after Acute Kidney Injury: A Competing-Risk Analysis of a Nationwide Cohort. *J. Clin. Med.* 2018, 7, 237.
84. Awdishu, L.; Connor, A.I.; Bouchard, J.; Macedo, E.; Chertow, G.M.; Mehta, R.L. Use of Estimating Equations for Dosing Antimicrobials in Patients with Acute Kidney Injury Not Receiving Renal Replacement Therapy. J. Clin. Med. 2018, 7, 211.
85. Wu, V.-C.; Shiao, C.-C.; Chi, N.-H.; Wang, C.-H.; Chueh, J.S.; Liou, H.-H.; Spapen, H.; Honore, P.M.; Chu, T.-S. Outcome Prediction of Acute Kidney Injury Biomarkers at Initiation of Dialysis in Critical Units. J. Clin. Med. 2018, 7, 202.
86. Selby, A.R.; Hall, R.G. Utilizing the Patient Care Process to Minimize the Risk of Vancomycin-Associated Nephrotoxicity. J. Clin. Med. 2019, 8, 781.
87. Chen, J.J.; Fan, P.C.; Kou, G.; Chang, S.W.; Chen, Y.T.; Lee, C.C.; et al. Meta-Analysis: Urinary Calprotectin for Discrimination of Intrinsic and Prerenal Acute Kidney Injury. J. Clin. Med. 2019, 8, 74.
88. Abassi, Z.; Rosen, S.; Lamothe, S.; Heyman, S.N. Why Have Detection, Understanding and Management of Kidney Hypoxic Injury Lagged Behind those for the Heart? J. Clin. Med. 2019, 8, 267.
89. Case, J.; Khan, S.; Khalid, R.; Khan, A. Epidemiology of acute kidney injury in the intensive care unit. Crit. Care Res. Pract. 2013, 2013, 497730.
90. Thongprayoon, C.; Lerjitbanjong, P.; Hansrivijit, P.; Crisafia, A.; Mao, M.A.; Watthanasuntorn, K.; Aeddula, N.R.; Bathini, T.; Kaewput, W.; Cheungpasitporn, W. Acute Kidney Injury in Patients Undergoing Cardiac Transplantation: A Meta-Analysis. Medicines 2019, 6, 108.
91. Thongprayoon, C.; Cheungpasitporn, W.; Srivali, N.; Kittanamongkolchai, W.; Greason, K.L.; Kashani, K.B. Incidence and risk factors of acute kidney injury following transcatheter aortic valve replacement. Nephrology 2016, 21, 1041–1046.
92. Kanduri, S.R.; Cheungpasitporn, W.; Thongprayoon, C.; Bathini, T.; Kovvuru, K.; Garla, V.; Medaura, J.; Vailla, P.; Kashani, K.B. Incidence and Mortality of Acute Kidney Injury in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-analysis. QJM Int. J. Med. 2020, 10.1093/qjmed/hcaa072.
93. Lagny, M.-G.; Jouret, F.; Koch, J.-N.; Blaffart, F.; Donneau, A.-F.; Albert, A.; Roediger, L.; Krzesinski, J.-M.; Defraigne, J.-O. Incidence and outcomes of acute kidney injury after cardiac surgery using either criteria of the RIFLE classification. BMJ Nephrol. 2015, 16, 76.
94. Vives, M.; Hernandez, A.; Parramon, F.; Estanyol, N.; Pardina, B.; Muñoz, A.; Alvarez, P.; Hernandez, C. Acute kidney injury after cardiac surgery: Prevalence, impact and management challenges. Int. J. Nephrol. Renovasc. Dis. 2019, 12, 153–166.
95. Mårtensson, J.; Bellomo, R. Sepsis-Induced Acute Kidney Injury. Crit. Care Clin. 2015, 31, 649–660.
96. Panitchote, A.; Mehkri, O.; Hastings, A.; Hanane, T.; Demirjian, S.; Torbic, H.; Mireles-Cabodevila, E.; Krishnan, S.; Duggal, A. Factors associated with acute kidney injury in acute respiratory distress syndrome. Ann. Intensive Care 2019, 9, 74.
97. Darmon, M.; Clec’H, C.; Adrie, C.; Argaud, L.; Allouchiche, B.; Azoulay, E.; Bouadma, L.; Garrouste-Orgeas, M.; Haouache, H.; Schwebel, C.; et al. Acute respiratory distress syndrome and risk of AKI among critically ill patients. Clin. J. Am. Soc. Nephrol. 2014, 9, 1347–1353.
98. Wijarnpreecha, K.; Thongprayoon, C.; Edmonds, P.J.; Cheungpasitporn, W. Associations of sugar- and artificially sweetened soda with nonalcoholic fatty liver disease: A systematic review and meta-analysis. QJM 2016, 109, 461–466.
99. Thongprayoon, C.; Cheungpasitporn, W.; Srivali, N.; Ungprasert, P.; Kittanamongkolchai, W.; Greason, K.L.; Kashani, K.B. Acute kidney injury after transcatheter aortic valve replacement: A systematic review and meta-analysis. Am. J. Nephrol. 2015, 41, 372–382.
100. Thongprayoon, C.; Cheungpasitporn, W.; Lin, J.; Mao, M.A.; Qian, Q. Acute kidney injury in octogenarians after heart valve replacement surgery: A study of two periods over the last decade. Clin. Kidney J. 2017, 10, 648–654.
101. Thongprayoon, C.; Cheungpasitporn, W.; Thamcharoen, N.; Ungprasert, P.; Kittanamongkolchai, W.; Mao, M.A.; Sakhuja, A.; Greason, K.L.; Kashani, K.B. Association of frailty status with acute kidney injury and mortality after transcatheter aortic valve replacement: A systematic review and meta-analysis. PLoS ONE 2017, 12, e0177157.
102. Thongprayoon, C.; Cheungpasitporn, W.; Srivali, N.; Kittanamongkolchai, W.; Sakhuja, A.; Greason, K.L.; Kashani, K.B. The association between renal recovery after acute kidney injury and long-term mortality after transcatheter aortic valve replacement. PLoS ONE 2017, 12, e0183350.
103. Sahuja, A.; Kashani, K.; Schold, J.; Cheungpasitporn, W.; Soltesz, E.; Demirjian, S. Hospital procedure volume does not predict acute kidney injury after coronary artery bypass grafting—a nationwide study. *Clin. Kidney J.* 2017, 10, 769–775.

104. Thongprayoon, C.; Cheungpasitporn, W.; Srivali, N.; Harrison, A.M.; Gunderson, T.M.; Kittanamongkolchai, W.; Greason, K.L.; Kashani, K.B. AKI after Transcatheter or Surgical Aortic Valve Replacement. *J. Am. Soc. Nephrol.* 2016, 27, 1854–1860.

105. Muriithi, A.K.; Nasr, S.H.; Leung, N. Utility of urine eosinophils in the diagnosis of acute interstitial nephritis. *Clin. J. Am. Soc. Nephrol.* 2013, 8, 1857–1862.

106. Nguyen, M.T.; Maynard, S.E.; Kimmel, P.L. Misapplications of commonly used kidney equations: Renal physiology in practice. *Clin. J. Am. Soc. Nephrol.* 2009, 4, 528–534.

107. Chawla, L.S.; Davison, D.; Brasha-Mitchell, E.; Koyner, J.L.; Arthur, J.; Shaw, A.; Tumlin, J.A.; Trevino, S.; Kimmel, P.L.; Seneff, M.G. Development and standardization of a furosemide stress test to predict the severity of acute kidney injury. *Crit. Care* 2013, 17, R207.

108. Koyner, J.L.; Davison, D.L.; Brasha-Mitchell, E.; Chalikonda, D.M.; Arthur, J.; Shaw, A.; Tumlin, J.A.; Trevino, S.A.; Bennett, M.R.; Kimmel, P.L.; et al. Furosemide stress test and biomarkers for the prediction of AKI severity. *J. Am. Soc. Nephrol.* 2016, 26, 2023–2031.

109. Thongprayoon, C.; Cheungpasitporn, W.; Kashani, K. Serum creatinine level, a surrogate of muscle mass, predicts mortality in critically ill patients. *J. Thorac. Dis.* 2016, 8, E305–E311.

110. Kashani, K.; Cheungpasitporn, W.; Ronco, C. Biomarkers of acute kidney injury: The pathway from discovery to clinical adoption. *Clin. Chem. Lab Med.* 2017, 55, 1074–1089.

111. Capasso, A.; Benigni, A.; Capitanio, U.; Danesh, F.R.; Di Marzo, V.; Gesualdi, L.; Grandaliano, G.; Jaimes, E.A.; Malyzsko, J.; Perazella, M.A.; et al. Summary of the International Conference on Onco-Nephrology: An emerging field in medicine. *Kidney Int.* 2019, 96, 555–567.

112. Parikh, C.R.; Coca, S.G.; Thiessen-Philbrook, H.; Shlipak, M.G.; Koyner, J.L.; Wang, Z.; Edelstein, C.L.; Devarajan, P.; Patel, U.D.; Zappitelli, M.; et al. Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. *J. Am. Soc. Nephrol.* 2011, 22, 1748–1757.

113. Siew, E.D.; Ware, L.B.; Bian, A.; Shintani, A.; Wickersham, N.; Cripps, B.; Ikizler, T.A. Distinct injury markers for the early detection and prognosis of incident acute kidney injury in critically ill adults with preserved kidney function. *Kidney Int.* 2013, 84, 786–794.

114. Srisawat, N.; Wen, X.; Lee, M.; Kong, L.; Elder, M.; Carter, M.; Unruh, M.; Finkel, K.; Vijayan, A.; Ramkumar, M.; et al. Urinary biomarkers and renal recovery in critically ill patients with renal support. *Clin. J. Am. Soc. Nephrol.* 2011, 6, 1815–1823.

115. Damman, K.; Masson, S.; Hillege, H.L.; Maggioni, A.P.; Voors, A.A.; Opasich, C.; Van Veldhuisen, D.J.; Montagna, L.; Cosmi, F.; Tognoni, G.; et al. Clinical outcome of renal tubular damage in chronic heart failure. *Eur. Heart J.* 2011, 32, 2705–2712.

116. Hall, I.E.; Yarlagadda, S.G.; Coca, S.G.; Wang, Z.; Doshi, M.; Devarajan, P.; Han, W.K.; Marcus, R.J.; Parikh, C.R. IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. *J. Am. Soc. Nephrol.* 2010, 21, 189–197.

117. Nauta, F.L.; Bakker, S.J.L.; Van Oeveren, W.; Navis, G.; Van Der Heide, J.J.H.; Van Goor, H.; De Jong, P.E.; Gansevoort, R.T. Albuminuria, proteinuria, and novel urine biomarkers as predictors of long-term allograft outcomes in kidney transplant recipients. *Am. J. Kidney Dis.* 2011, 57, 733–743.

118. Zhang, W.R.; Garg, A.X.; Coca, S.G.; Devereaux, P.J.; Eikelboom, J.; Kavsak, P.; McArthur, E.; Thiessen-Philbrook, H.; Shortt, C.; Shlipak, M.; et al. Plasma IL-6 and IL-10 Concentrations Predict AKI and Long-Term Mortality in Adults after Cardiac Surgery. *J. Am. Soc. Nephrol.* 2015, 26, 3123–3132.

119. Arthur, J.; Hill, E.G.; Alge, J.; Lewis, E.C.; Neely, B.A.; Janech, M.G.; Tumlin, J.A.; Chawla, L.S.; Shaw, A. Evaluation of 32 urine biomarkers to predict the progression of acute kidney injury after cardiac surgery. *Kidney Int.* 2014, 85, 431–438.

120. Parikh, C.R.; Abraham, E.; Ancukiewicz, M.; Edelstein, C.L. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. *J. Am. Soc. Nephrol.* 2005, 16, 3046–3052.

121. Nejat, M.; Pickering, J.W.; Walker, R.J.; Westhuyzen, J.; Shaw, G.M.; Frampton, C.M.; et al. Urinary cystatin C is diagnostic of acute kidney injury and sepsis, and predicts mortality in the intensive care unit. *Crit. Care* 2010, 14, R85.
122. Doi, K.; Negishi, K.; Ishizu, T.; Katagiri, D.; Fujita, T.; Matsubara, T.; Yahagi, N.; Sugaya, T.; Noiri, E. Evaluation of new acute kidney injury biomarkers in a mixed intensive care unit. Crit. Care Med. 2011, 39, 2464–2469.

123. Bell, M.; Larsson, A.; Venge, P.; Bellomo, R.; Martensson, J. Assessment of cell-cycle arrest biomarkers to predict early and delayed acute kidney injury. Dis. Markers 2015, 2015, 158658.

124. Meersch, M; Schmidt, C.; Van Aken, H.; Martens, S.; Rossaint, J.; Singbartl, K.; Goerlich, D.; Kellum, J.A.; Zarbock, A. Urinary TIMP-2 and IGFBP7 as early biomarkers of acute kidney injury and renal recovery following cardiac surgery. PloS ONE 2014, 9, e93460.

125. Heller, F.; Frischmann, S.; Grunbaum, M.; Zidek, W.; Westhoff, T.H. Urinary calprotectin and the distinction between prerenal and intrinsic acute kidney injury. Clin. J. Am. Soc. Nephrol. 2011, 6, 2347–2355.

126. Yang, X.; Chen, C.; Tian, J.; Zha, Y.; Xiong, Y.; Sun, Z.; Chen, P.; Li, J.; Yang, T.; Ma, C.; et al. Urinary Angiotensinogen Level Predicts AKI in Acute Decompensated Heart Failure: A Prospective, Two-Stage Study. J. Am. Soc. Nephrol. 2015, 26, 2032–2041.

127. Du, J.; Cao, X.; Zou, L.; Chen, Y.; Guo, J.; Chen, Z.; Hu, S.-S.; Zheng, Z. MicroRNA-21 and risk of severe acute kidney injury and poor outcomes after adult cardiac surgery. PLoS ONE 2013, 8, e63390.

128. Leblanc, M.; Kellum, J.A.; Gibney, R.T.; Lieberthal, W.; Tumlin, J.; Mehta, R. Risk factors for acute renal failure: Inherent and modifiable risks.Curr. Opin. Crit. Care 2005, 11, 533–536.

129. Cheungpasitporn, W.; Thongprayoon, C.; Kashani, K. Transcatheter Aortic Valve Replacement: A Kidney’s Perspective. J. Renal Inj. Prev. 2016, 5, 1–7.

130. Cartin-Ceba, R.; Kashiouris, M.; Plataki, M.; Kor, D.J.; Gajic, O.; Casey, E.T. Risk factors for development of acute kidney injury in critically ill patients: A systematic review and meta-analysis of observational studies. Crit. Care Res. Pract. 2012, 2012, 691013.

131. Cheungpasitporn, W.; Thongprayoon, C.; Kashani, K. Updates on the risk factors of acute kidney injury after transcatheter aortic valve replacement. J. Renal Inj. Prev. 2017, 6, 16–7.

132. Thongprayoon, C.; Cheungpasitporn, W.; Gillaspie, E.A.; Greason, K.L.; Kashani, K.B. Association of blood transfusion with acute kidney injury after transcatheter aortic valve replacement: A meta-analysis. World J. Nephrol. 2016, 5, 482–488.

133. Odutayo, A.; Wong, C.X.; Farkouh, M.; Altman, U.G.; Hopewell, S.; Emdin, C.A.; Hunn, B.H. AKI and Long-Term Risk for Cardiovascular Events and Mortality. J. Am. Soc. Nephrol. 2017, 28, 377–387.

134. Pickering, J.W.; Blunt, I.R.H.; Than, M.P. Acute Kidney Injury and mortality prognosis in Acute Coronary Syndrome patients: A meta-analysis. Nephrology 2018, 23, 237–246.

135. Shi, Q.; Hong, L.; Mu, X.; Zhang, C.: Chen, X. Meta-analysis for outcomes of acute kidney injury after cardiac surgery. Medicine 2016, 95, e5558.

136. Giordana, F.; D’Ascenzo, F.; Nijhoff, F.; Moretti, C.; D’Amico, M.; Biondi-Zocccai, G.; Sinning, J.M.; Nickenig, G.; Van Mieghem, N.M.; Chieffo, A.; et al. Meta-analysis of predictors of all-cause mortality after transcatheter aortic valve implantation. Am. J. Cardiol. 2014, 114, 1447–1455.

137. Abdul Salim, S.; Tran, H.; Thongprayoon, C.; Fülöp, T.; Cheungpasitporn, W. Comparison of drug-coated balloon angioplasty versus conventional angioplasty for arteriovenous fistula stenosis: Systematic review and meta-analysis. J. Vasc. Access 2019, doi:10.1177/1129729819878612.

138. De Carvalho, J.R.; Villela-Nogueira, C.A.; Luiz, R.R.; Guzzo, P.L.; Rosa, J.M.D.S.; Rocha, E.; Coelho, H.S.M.; Perez, R.D.M. Acute kidney injury network criteria as a predictor of hospital mortality in cirrhotic patients with ascites. J. Clin. Gastroenterol. 2012, 46, e21–e26.

139. Mandelbaum, T.; Scott, D.J.; Lee, J.; Mark, R.G.; Malhotra, A.; Waikar, S.S.; Howell, M.D.; Talmor, D. Outcome of critically ill patients with acute kidney injury using the Acute Kidney Injury Network criteria. Crit. Care Med. 2011, 39, 2659–2664.

140. Wongrapanich, S.; Kallis, C.; Prasad, P.; Rangaswami, J.; Rosenzweig, A. The Study of Rhabdomyolysis in the Elderly: An Epidemiological Study and Single Center Experience. Aging Dis. 2018, 9, 1–7.

141. Vandenbergh, W.; Gevaert, S.; Kellum, J.A.; Bagshaw, S.M.; Peperstraete, H.; Herck, I.; Decruyenaere, J.; Hoste, E. Acute Kidney Injury in Cardiorenal Syndrome Type 1 Patients: A Systematic Review and Meta-Analysis. Cardiorenal Med. 2016, 6, 116–128.

142. Folkestad, T.; Brurberg, K.G.; Nordhuus, K.M.; Tveiten, C.K.; Gutormsen, A.B.; Os, I.; Beitland, S. Acute kidney injury in burn patients admitted to the intensive care unit: A systematic review and meta-analysis. Crit. Care 2020, 24, 2–11.
Arnold, J.; Ng, K.P.; Sims, D.; Gill, P.; Cockwell, P.; Ferro, C. Incidence and impact on outcomes of acute kidney injury after a stroke: A systematic review and meta-analysis. *BMC Nephrol.* **2018**, *19*, 283.

Juwon, L.; Jang, G.; Kim, S.; Kim, D.; Lee, J.; Park, H.; Lee, J.; Kim, S.; Kim, Y.; Kim, S.Y.; et al. Outcomes of acute kidney injury patients with and without cancer. *Ren. Fail.* **2015**, *37*, 332–337.

Barakat, M.F.; McDonald, H.I.; Collier, T.J.; Smeeth, L.; Nitsch, D.; Quint, J.K. Acute kidney injury in stable COPD and at exacerbation. *Int. J. Chron. Obstruct. Pulmon. Dis.* **2015**, *10*, 2067–2077.

Fiaccadori, E.; Lombardi, M.; Leonardi, S.; Rotelli, C.F.; Tortorella, G.; Borghetti, A. Prevalence and clinical outcome associated with preexisting malnutrition in acute renal failure: A prospective cohort study. *J. Am. Soc. Nephrol.* **1999**, *10*, 581–593.

Bai, Z.; Primignani, M.; Guo, X.; Zheng, K.; Li, H.; Qi, X. Incidence and mortality of renal dysfunction in cirrhotic patients with acute gastrointestinal bleeding: A systematic review and meta-analysis. *Expert Rev. Gastroenterol. Hepatol.* **2019**, *13*, 1181–1188.

Fiaccadori, E.; Maggiore, U.; Clima, B.; Melfa, L.; Rotelli, C.; Borghetti, A. Incidence, risk factors, and prognosis of gastrointestinal hemorrhage complicating acute renal failure. *Kidney Int.* **2001**, *59*, 1510–1519.

Thongprayoon, C.; Cheungpasitporn, W.; Srivali, N.; Harrison, A.; Kittanamongkolchai, W.; Greason, K.L.; Kashani, K.B. Transapical versus transfemoral approach and risk of acute kidney injury following transcatheter aortic valve replacement: A propensity-adjusted analysis. *Ren. Fail.* **2017**, *39*, 13–18.

Thongprayoon, C.; Cheungpasitporn, W.; Gillaspie, E.A.; Greason, K.L.; Kashani, K.B. The risk of acute kidney injury following transapical versus transfemoral transcatheter aortic valve replacement: A systematic review and meta-analysis. *Clin. Kidney J.* **2016**, *9*, 560–566.

Ferner, A.; Haase, N.; Guttormsen, A.B.; Tenhunen, J.; Klemenzson, G.; Åneman, A. Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. *N. Engl. J. Med.* **2012**, *367*, 124–134.

Patel, A.; Pieper, K.; Myburgh, J.A.; Perkovic, V.; Finfer, S.; Yang, Q.; Li, Q.; Billot, L. Reanalysis of the Crystalloid versus Hydroxyethyl Starch Trial (CHEST). *N. Engl. J. Med.* **2017**, *377*, 298–300.

Semler, M.W.; Selz, W.H.; Wanderer, J.P.; Ehrenfeld, J.M.; Wang, L.; Byrne, D.W.; Stollings, J.L.; Kumar, A.B.; Hughes, C.G.; Hernandez, A.; et al. Balanced Crystalloids versus Saline in Critically Ill Adults. *N. Engl. J. Med.* **2018**, *378*, 829–839.

Selz, W.H.; Semler, M.W.; Wanderer, J.P.; Wang, L.; Byrne, D.W.; Collins, S.P.; Slovis, C.M.; Lindsell, C.J.; Ehrenfeld, J.M.; Siew, E.D.; et al. Balanced Crystalloids versus Saline in Noncritically Ill Adults. *N. Engl. J. Med.* **2018**, *378*, 819–828.

Cheungpasitporn, W.; Thongprayoon, C.; Brabec, B.A.; Edmonds, P.J.; O’Corragain, O.A.; Erickson, S.B. Oral hydration for prevention of contrast-induced acute kidney injury in elective radiological procedures: A systematic review and meta-analysis of randomized controlled trials. *N. Am. J. Med. Sci.* **2014**, *6*, 618–624.

Cheungpasitporn, W.; Thongprayoon, C.; A Mao, M.; A Mao, S.; D’Costa, M.R.; Kittanamongkolchai, W.; Kashani, K.B. Contrast-induced acute kidney injury in kidney transplant recipients: A systematic review and meta-analysis. *World J. Transplant.* **2017**, *7*, 81–87.

Thongprayoon, C.; Cheungpasitporn, W.; Srivali, N.; Erickson, S.B. Admission serum magnesium levels and the risk of acute respiratory failure. *Int. J. Clin. Pract.* **2015**, *69*, 1303–1308.

Thamcharoen, N.; Thongprayoon, C.; Edmonds, P.J.; Cheungpasitporn, W. Periprocedural Nebivolol for the Prevention of Contrast-Induced Acute Kidney Injury: A Systematic Review and Meta-analysis. *N. Am. J. Med. Sci.* **2015**, *7*, 446–451.

Cheungpasitporn, W.; Thongprayoon, C.; Srivali, N.; O’Corragain, O.A.; Edmonds, P.; Ungprasert, P.; Kittanamongkolchai, W.; Erickson, S.B. Preoperative renin-angiotensin system inhibitors use linked to reduced acute kidney injury: A systematic review and meta-analysis. *Nephrol. Dial. Transplant.* **2015**, *30*, 978–988.

Tomson, C.; Tomlinson, L.A. Stopping RAS Inhibitors to Minimize AKI: More Harm than Good? *Clin. J. Am. Soc. Nephrol.* **2019**, *14*, 617–619.

Ungprasert, P.; Cheungpasitporn, W.; Crowson, C.S.; Matteson, E.L. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. *Eur. J. Intern. Med.* **2015**, *26*, 285–291.

O’Reilly, P.; Tolwani, A. Renal replacement therapy III: IHD, CRRT, SLED. *Crit. Care Clin.* **2005**, *21*, 367–378.

Tolwani, A. Continuous renal-replacement therapy for acute kidney injury. *N. Engl. J. Med.* **2012**, *367*, 2505–2514.
164. Cerdá, J.; Ronco, C. Modalities of continuous renal replacement therapy: Technical and clinical considerations. *Semin. Dial.* 2009, 22, 114–122.

165. Kellum, J.A.; Mehta, R.L.; Angus, D.C.; Palevsky, P.; Ronco, C. The first international consensus conference on continuous renal replacement therapy. *Kidney Int.* 2002, 62, 1855–1863.

166. Cerdá, J.; Sheinfeld, G.; Ronco, C. Fluid overload in critically ill patients with acute kidney injury. *Blood Purif.* 2010, 29, 331–338.

167. Tandukar, S.; Palevsky, P.M. Continuous Renal Replacement Therapy: Who, When, Why, and How. *Chest* 2019, 155, 626–638.

168. Ronco, C.; Bellomo, R.; Ricci, Z. Continuous renal replacement therapy in critically ill patients. *Nephrol. Dial Transplant.* 2001, 16, 67–72.

169. Schwenger, V.; Weigand, M.A.; Hoffmann, O.; Dikow, R.; Kihm, L.P.; Seckinger, J.; Miftari, N.; Schaier, M.; Hofer, S.; Haar, C.; et al. Sustained low efficiency dialysis using a single-pass batch system in acute kidney injury—A randomized interventional trial: The REnal Replacement Therapy Study in Intensive Care Unit PatiEnts. *Crit. Care* 2012, 16, R140.

170. Villa, G.; Neri, M.; Bellomo, R.; Cerdá, J.; De Gaudio, A.R.; De Rosa, S.; Garzotto, F.; Honore, P.M.; Kellum, J.A.; Lorenzin, A.; et al. Nomenclature for renal replacement therapy and blood purification techniques in critically ill patients: Practical applications. *Crit. Care* 2016, 20, 283.

171. Lins, R.L.; Elseviers, M.M.; Van Der Niepen, P.; Hoste, E.; Malbrain, M.L.; Damas, P.; Devriendt, J. Intermittent versus continuous renal replacement therapy for acute kidney injury patients admitted to the intensive care unit: Results of a randomized clinical trial. *Nephrol. Dial Transplant.* 2009, 24, 512–518.

172. Vinsonneau, C.; Camus, C.; Combes, A.; De Beauregard, M.A.C.; Klouche, K.; Boulain, T.; Pallot, J.-L.; Chiche, J.-D.; Taupin, P.; Landais, P.; et al. Continuous venovenous haemodialfiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: A multicentre randomised trial. *Lancet* 2006, 368, 379–385.

173. Nash, D.M.; Przech, S.; Wald, R.; O’Reilly, D. Systematic review and meta-analysis of renal replacement therapy modalities for acute kidney injury in the intensive care unit. *J. Crit. Care* 2017, 41, 138–144.

174. Friedrich, J.O.; Wald, R.; Bagshaw, S.M.; Burns, K.E.; Adhikari, N.K. Hemoﬁltration compared to hemodialysis for acute kidney injury: Systematic review and meta-analysis. *Crit. Care* 2012, 16, R146.

175. Ronco, C.; Bellomo, R.; Homel, P.; Brendolan, A.; Dan, M.; Piccinni, P.; La Greca, G. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: A prospective randomised trial. *Lancet* 2000, 356, 26–30.

176. Intensity of Renal Support in Critically Ill Patients with Acute Kidney Injury. *N. Engl. J. Med.* 2008, 359, 7–20.

177. Bellomo, R.; Cass, A.; Cole, L.; Finfer, S.; Gallagher, M.P.; Billot, L.; McArthur, C.; McGuinness, S.; Myburgh, J.; Norton, R.; et al. Intensity of continuous renal-replacement therapy in critically ill patients. *N. Engl. J. Med.* 2009, 361, 1627–1638.

178. Clark, E.; Molnar, A.O.; Joannes-Boyau, O.; Honoré, P.M.; Sikora, L.; Bagshaw, S.M. High-volume hemofiltration for septic acute kidney injury: A systematic review and meta-analysis. *Crit. Care* 2014, 18, R7.

179. Combes, A.; Cozic, N.; Guidon, C.; Thiranos, J.-C.; Rigal, J.-C.; Benhaoua, H.; Abry, B.; Chastre, J.; Bréchot, N.; Amour, J.; et al. Early High-Volume Hemofiltration versus Standard Care for Post-Cardiac Surgery Shock. The HEROICS Study. *Am. J. Respir. Crit. Care Med.* 2015, 192, 1179–1190.

180. Gaudry, S.; Hajage, D.; Schortgen, F.; Martin-Lefevre, L.; Pons, B.; Boulet, E.; Boyer, A.; Chevrel, G.; Lerolle, N.; Carpenter, D.; et al. Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. *N. Engl. J. Med.* 2016, 375, 122–133.

181. Barbar, S.D.; Clerc-Jehl, R.; Bourredjem, A.; Hernu, R.; Montini, F.; Brûyère, R.; Lebert, C.; Bohé, J.; Badie, J.; Eraldi, J.-P.; et al. Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis. *N. Engl. J. Med.* 2018, 379, 1431–1442.

182. Zarbock, A.; Kellum, J.A.; Schmidt, C.; Van Aken, H.; Wempe, C.; Pavnetsdóttir, H.; Boanta, A.; Gerß, J.; Meersch, M. Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. *JAMA* 2016, 315, 2190–2199.

183. Zhang, Z. No “optimal timing” of renal-replacement therapy in critically ill patients with acute kidney injury. *Ann. Transl. Med.* 2018, 23.
184. Gaudry, S.; Hajage, D.; Martin-Lefevre, L.; Louis, G.; Moschietto, S.; Beauport, D.T.; La Combe, B.; Pons, B.; De Prost, N.; Besset, S.; et al. The Artificial Kidney Initiation in Kidney Injury 2 (AKIKI2): Study protocol for a randomized controlled trial. *Trials* **2019**, *20*, 726.

185. Smith, O.M.; Wald, R.; Adhikari, N.K.; Pope, K.; Weir, M.A.; Bagshaw, S.M. Standard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: Study Protocol for a Multi-National, Multi-Center, Randomized Controlled Trial. *Can. J. Kidney Health Dis.* **2019**, *6*, 320.

186. Sutherland, S.M. Electronic Health Record-Enabled Big-Data Approaches to Nephrotoxin-Associated Acute Kidney Injury Risk Prediction. *Pharmacotherapy* **2018**, *38*, 804–812.

187. Basu, R.K. Dynamic Biomarker Assessment: A Diagnostic Paradigm to Match the AKI Syndrome. *Front. Pediatr.* **2019**, *7*, 535.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).